HUNAN WARRANT PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42 CNY | -4.11% |
|
-9.85% | -14.18% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 4,591 | 3,940 | - | - |
| Enterprise Value (EV) 1 | 4,591 | 3,940 | 3,940 | 3,940 |
| P/E ratio | 21.8 x | - | - | - |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 2.25 x | 1.9 x | 1.62 x |
| EV / Revenue | - | 2.25 x | 1.9 x | 1.62 x |
| EV / EBITDA | - | 10.8 x | 8.97 x | 7.68 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | 2.07 x | 1.86 x | 1.66 x |
| Nbr of stocks (in thousands) | 93,800 | 93,800 | - | - |
| Reference price 2 | 48.94 | 42.00 | 42.00 | 42.00 |
| Announcement Date | 2/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | 1,753 | 2,076 | 2,426 |
| EBITDA 1 | - | 364 | 439 | 513 |
| EBIT 1 | - | 316 | 382 | 450 |
| Operating Margin | - | 18.02% | 18.4% | 18.55% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | 211.4 | - | - | - |
| Net margin | - | - | - | - |
| EPS | 2.250 | - | - | - |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 2/25/24 | - | - | - |
1CNY in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 |
|---|---|
| Net sales 1 | 372.9 |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income | - |
| Net margin | - |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 4/19/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 13.9% | 15.2% | 16% |
| ROA (Net income/ Total Assets) | - | 11% | 12.1% | 12.8% |
| Assets | - | - | - | - |
| Book Value Per Share 1 | - | 20.30 | 22.60 | 25.30 |
| Cash Flow per Share | - | - | - | - |
| Capex 2 | - | 96 | 80 | 64 |
| Capex / Sales | - | 5.48% | 3.85% | 2.64% |
| Announcement Date | 2/25/24 | - | - | - |
1CNY2CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
42
CNY
Average target price
59
CNY
Spread / Average Target
+40.48%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.18% | 569M | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- 688799 Stock
- Financials Hunan Warrant Pharmaceutical Co.,Ltd
